Literature DB >> 15951160

The epidemiology of generalized anxiety disorder in Europe.

Roselind Lieb1, Eni Becker, Carlo Altamura.   

Abstract

The objective of this paper is to provide a review on available data to date on the epidemiology of GAD in Europe, and to highlight areas for future research. MEDLINE searches were performed and supplemented by consultations with experts across Europe to identify non-published reports. Despite variations in the design of studies, available data suggest that (a) about 2% of the adult population in the community is affected (12-month prevalence), (b) GAD is one of the most frequent (up to 10%) of all mental disorders seen in primary care, (c) GAD is a highly impairing condition often comorbid with other mental disorders, (d) GAD patients are high utilizers of healthcare resources, and (e) despite the high prevalence of GAD in primary care, its recognition in general practice is relatively low. Marked data deficits are: lack of data from eastern European countries, lack of information about the natural course of GAD in unselected samples, the vulnerability and risk factors involved in the aetiology of GAD and lack of data about adequate and inappropriate treatments in GAD patients as well as the associated and societal costs of GAD.

Entities:  

Mesh:

Year:  2005        PMID: 15951160     DOI: 10.1016/j.euroneuro.2005.04.010

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  45 in total

Review 1.  Finding gene-environment interactions for generalised anxiety disorder.

Authors:  Alice M Gregory; Jennifer Y F Lau; Thalia C Eley
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

2.  Generalised anxiety disorder: the importance of life context and social factors.

Authors:  Lynda Tait; Giles Berrisford
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

3.  The burden of generalized anxiety disorder in Canada.

Authors:  Louise Pelletier; Siobhan O'Donnell; Louise McRae; Jean Grenier
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-02       Impact factor: 3.240

4.  Vitamin D supplementation ameliorates severity of generalized anxiety disorder (GAD).

Authors:  Alaa Eid; Sawsan Khoja; Shareefa AlGhamdi; Hadeil Alsufiani; Faten Alzeben; Nasim Alhejaili; Haythum O Tayeb; Frank I Tarazi
Journal:  Metab Brain Dis       Date:  2019-09-02       Impact factor: 3.584

Review 5.  [Generalized anxiety disorder with comorbidity. Treatment with pregabalin].

Authors:  D Lauer; L Hölzel; M Hornyak
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

6.  Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristics.

Authors:  M Burstein; K Beesdo-Baum; J-P He; K R Merikangas
Journal:  Psychol Med       Date:  2014-01-02       Impact factor: 7.723

Review 7.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Recognizing and managing anxiety disorders in primary health care in Turkey.

Authors:  Mehtap Kartal; Ozlem Coskun; Nesrin Dilbaz
Journal:  BMC Fam Pract       Date:  2010-04-28       Impact factor: 2.497

9.  Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.

Authors:  Montserrat Vera-Llonch; Ellen Dukes; Javier Rejas; Oleg Sofrygin; Marko Mychaskiw; Gerry Oster
Journal:  Eur J Health Econ       Date:  2009-06-09

10.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Trevor R Norman; James S Olver
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.